Format

Send to

Choose Destination
J Mol Cell Biol. 2009 Oct;1(1):17-9. doi: 10.1093/jmcb/mjp011. Epub 2009 Aug 14.

CCR3: Shedding new light on a dark problem?

Author information

1
Yale University School of Medicine, New Haven, CT 06510, USA. alan.mason@yale.edu

Abstract

A recent work by Ambati et al. represents a bold step towards a more effective diagnosis and treatment of age-related macular degeneration, with the new evidence showing that CCR3, a chemokine receptor, is an early marker of and potential therapeutic target for choroidal neovascularization development. In the wake of such a novel and significant finding, additional illumination to confirm and consolidate the promise shown by CCR3 will soon follow.

PMID:
19684049
DOI:
10.1093/jmcb/mjp011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center